Santander UK Plc (SAN) 10 3/8% Non Cum Stlg Pref GBP1
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Santander shares drop despite Q3 beat as UK results delayed
29 October 2024 09:15
(Sharecast News) - Shares in Banco Santander slumped on Tuesday despite record third-quarter profits beating analysts' forecasts, as the Spanish banking group announced it was delaying the results of...
-
Santander on track to return €6bn to shareholders
22 March 2024 10:53
(Sharecast News) - Spain's Banco Santander said on Friday it was on track to return more than €6bn to shareholders in 2024, following a strong start to the year.
-
Santander reportedly lodges complaint about Nationwide ad
8 February 2024 13:50
(Sharecast News) - Santander UK has filed a formal complaint with Britain's advertising regulator over a Nationwide campaign which it claims "discredits and denigrates" the high street banking...
-
GSK settles California Zantac lawsuit
11 October 2023 11:51
(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.
-
AstraZeneca, Sanofi infant respiratory treatment gets US approval
18 July 2023 08:10
(Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and...
-
UK bank pass annual stress tests, says BoE
12 July 2023 07:21
(Sharecast News) - Eight major UK banks have passed annual capital stress tests and were well positioned to support households and businesses through a period of rising interest rates, the Bank of England...
-
AstraZeneca, Sanofi respiratory drug gets EU marketing go-ahead
16 September 2022 07:02
(Sharecast News) - AstraZeneca and Sanofi said their Beyfortus drug for the prevention of lower respiratory tract disease in newborns and infants has been recommended for marketing authorisation in the...
-
GSK to 'vigorously defend' Zantac claims; Haleon says not a party to claims
12 August 2022 07:26
(Sharecast News) - GlaxoSmithKline said on Friday that it would "vigorously defend" all claims related to its discontinued heartburn drug Zantac.
-
GSK, Haleon, Sanofi slump amid Zantac litigation woes
11 August 2022 12:35
(Sharecast News) - Shares in GlaxoSmithKline, Haleon and Sanofi tumbled on Thursday amid concerns about legal proceedings related to Glaxo's former blockbuster heartburn drug Zantac.
-
GSK and Sanofi seek approval for Covid-19 jab
23 February 2022 11:23
(Sharecast News) - GlaxoSmithKline and Sanofi are to seek regulatory approval for their Covid-19 vaccine candidate following successful efficacy trials.
-
Santander sees annual profits surge
2 February 2022 12:01
(Sharecast News) - Banco Santander reported a surge in annual profits on Wednesday, as the global economy recovered from the worst of the pandemic.
-
GSK-Sanofi Covid jab shows 'strong' immune response
15 December 2021 07:05
(Sharecast News) - A Covid-19 vaccine booster being developed by GlaxoSmithKline and Sanofi has been shown to be effective across all age groups tested, according to data released by the UK drugs firm on...
Company announcements Announcements
No company announcements about Santander UK Plc 10 3/8% Non Cum Stlg Pref GBP1 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.